Letter to the editor: Anti-RAS drugs and SARS-Co V-2 infection

作     者：Jingwei Bian Rongsheng Zhao Suodi Zhai Zijian Li Jingwei Bian;Rongsheng Zhao;Suodi Zhai;Ziiian Li

作者机构：Department of PharmacyPeking University Third HospitalBeijing 100083China Department of Cardiology and Institute of Vascular MedicinePeking University Third HospitalKey Laboratory of Cardiovascular Molecular Biology and Regulatory PeptidesMinistry of HealthKey Laboratory of Molecular Cardiovascular SciencesMinistry of EducationBeijing Key Laboratory of Cardiovascular Receptors ResearchBeijing 100083China 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2020年第10卷第7期

页      面：1251-1252页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 10[医学] 

基　　金：support from the National Natural Science Foundation of China(91939301,81820108031,91539123,and 81471893) Beijing Municipal Natural Science Foundation(7172235,China) 

主　　题：ACE2 drugs SARS 

摘      要：To the Editor:Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has spread rapidly throughout the world.It has already posed a great threat to global public health security.Angiotensin-converting enzyme 2(ACE2)has been identified as the major receptor of SARS-Co V-2.